Testosterone Enanthate Cost in Arizona (2026): Cash Prices, Insurance, and Savings Options

What Does Testosterone Enanthate Actually Cost in Arizona Right Now?

Arizona residents filling a testosterone enanthate prescription in 2026 can expect to pay around $70 per month at retail pharmacies without insurance. This figure reflects the average cash price across major chains like CVS, Walgreens, and Walmart locations statewide, though individual store pricing varies by 20% to 40%.

The manufacturer list price sits at $120 per month, but almost nobody pays that. Pharmacy benefit managers negotiate rebates, discount card platforms undercut the sticker price, and generic availability keeps competition active. A 1 mL vial of 200 mg/mL testosterone enanthate (the most commonly prescribed concentration) represents the standard monthly supply for patients on 100 mg to 200 mg weekly protocols [1].

Pricing splits into three tiers across the state. Brand-name Delatestryl, the original testosterone enanthate product approved by the FDA, commands the highest price point [2]. Generic testosterone enanthate from manufacturers like Perrigo and Hikma costs significantly less. Compounded testosterone enanthate from 503A pharmacies averages $80 per month, sometimes higher depending on concentration, carrier oil selection, and whether the pharmacy adds bacteriostatic water or specialized packaging.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by at least two morning total testosterone levels below 300 ng/dL [3]. Arizona clinicians follow this standard when initiating prescriptions, and the diagnostic workup itself (two serum testosterone draws plus a metabolic panel) typically runs $150 to $300 out of pocket if uninsured.

Price-conscious patients should know that multi-dose 10 mL vials offer a better per-dose cost than single-use 1 mL vials. A 10 mL vial of 200 mg/mL generic testosterone enanthate can cost $90 to $150 out of pocket and lasts 10 to 20 weeks depending on dose, translating to roughly $30 to $60 per month.

Does Arizona Medicaid Cover Testosterone Enanthate?

Arizona's Medicaid program (AHCCCS) does not cover testosterone enanthate for male hypogonadism as of 2026. This exclusion applies across all AHCCCS managed care plans, including Mercy Care, Banner University Family Care, and Arizona Complete Health.

The coverage gap affects a substantial population. Arizona expanded Medicaid under the ACA, and roughly 2.4 million residents are enrolled in AHCCCS. Men with confirmed hypogonadism who rely on AHCCCS face full out-of-pocket responsibility for testosterone replacement therapy. The AHCCCS formulary classifies androgens for male hypogonadism as a non-covered benefit, a policy that has remained unchanged through multiple formulary review cycles.

This situation is not unique to Arizona. A 2021 analysis published in the Journal of the Endocrine Society found that Medicaid coverage for testosterone replacement varies widely by state, with roughly 40% of state Medicaid programs imposing significant restrictions or outright exclusions on androgen therapy for adult males [4]. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone levels below 275 ng/dL, demonstrated that testosterone treatment improved sexual function, physical activity, and mood over 12 months [5]. Despite this evidence, Medicaid formularies have been slow to respond.

AHCCCS members do have a workaround. Patients can appeal through the AHCCCS prior authorization process by documenting two confirmed low testosterone levels, symptoms of hypogonadism, and absence of contraindications. Success rates on appeal are low (estimated at fewer than 15% based on provider reports), but the pathway exists. Alternatively, AHCCCS members can pay cash at the retail prices described above.

Which Commercial Insurance Plans Cover TRT in Arizona?

Most major commercial insurers operating in Arizona cover testosterone enanthate with prior authorization. The prior auth process typically requires documentation of two morning serum testosterone levels below 300 ng/dL, clinical symptoms, and confirmation that the prescriber has ruled out secondary causes.

Blue Cross Blue Shield of Arizona, UnitedHealthcare, Cigna, and Aetna all include generic testosterone enanthate on their formularies. Copays range from $10 to $45 per month depending on the plan tier and whether the medication falls under Tier 1 (preferred generic) or Tier 2 (non-preferred generic). Brand-name Delatestryl is rarely covered without a Tier Exception request.

The American Urological Association's 2018 guideline on testosterone deficiency states: "Testosterone therapy should be offered to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [6]. Insurance medical directors generally align prior authorization criteria with this recommendation, requiring symptom documentation alongside laboratory confirmation.

For patients on high-deductible health plans, the effective cost before meeting the deductible mirrors cash pricing. A patient with a $3,000 deductible will pay the pharmacy's contracted rate (often $50 to $80 per month for generic testosterone enanthate) until the deductible is satisfied. After that, the copay drops to the plan's generic tier amount.

Self-funded employer plans present a wildcard. Large Arizona employers like Raytheon, Banner Health, and Freeport-McMoRan administer their own pharmacy benefits, and coverage decisions can differ from standard commercial formularies. Patients should call the number on the back of their insurance card and request a formulary check before assuming coverage.

Is Compounded Testosterone Enanthate Legal in Arizona?

Yes. Arizona permits licensed 503A compounding pharmacies to prepare testosterone enanthate for individual patients with valid prescriptions. This is fully legal under both federal law (the Drug Quality and Security Act of 2013) and the Arizona State Board of Pharmacy regulations.

A 503A pharmacy compounds medications on a patient-specific basis after receiving a prescription. This differs from 503B outsourcing facilities, which can produce compounded drugs in larger batches without patient-specific prescriptions. Both categories operate in Arizona, though patients seeking compounded testosterone enanthate will most commonly interact with 503A pharmacies.

The FDA's guidance on compounding distinguishes between these two categories clearly [7]. For testosterone enanthate specifically, the compounded product is not FDA-approved (only commercially manufactured versions carry FDA approval), but compounding pharmacies can legally prepare it using USP-grade testosterone enanthate powder, appropriate carrier oils (typically cottonseed or sesame oil), and benzyl alcohol as a preservative.

Arizona-based 503A pharmacies offering compounded testosterone enanthate include both brick-and-mortar locations in Phoenix, Tucson, Scottsdale, and Flagstaff, as well as pharmacies that ship statewide. Pricing averages $80 per month for a standard 200 mg/mL concentration in a 10 mL vial, though some pharmacies charge $60 to $100 depending on the formulation.

One advantage of compounded testosterone enanthate: customization. Prescribers can specify non-standard concentrations (250 mg/mL or 300 mg/mL), alternative carrier oils for patients with cottonseed allergies, or combination formulations that include testosterone enanthate with other compounds. The trade-off is that compounded products do not undergo the same FDA manufacturing oversight as commercially produced generics.

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and principal investigator of the Testosterone Trials, noted in a 2018 Endocrine Society presentation: "The choice between commercially manufactured and compounded testosterone should be guided by clinical need, patient preference, and a clear understanding of the regulatory differences between these products" [5].

Can You Get Testosterone Enanthate via Telehealth in Arizona?

Arizona allows telehealth prescribing of testosterone enanthate with no in-person visit requirement for the initial consultation. The Arizona Telemedicine Program, one of the oldest in the country, has supported remote prescribing of controlled substances since 2020 under pandemic-era flexibilities that were later codified into permanent state law.

The Ryan Haight Act at the federal level requires a valid prescriber-patient relationship before prescribing Schedule III controlled substances (testosterone enanthate is Schedule III). Arizona satisfies this requirement through synchronous video consultations. A prescriber licensed in Arizona can evaluate a patient via video, order laboratory work, review results, and issue a prescription to any Arizona pharmacy.

Several telehealth platforms serve Arizona TRT patients, including HealthRX, Hone Health, and Defy Medical. The consultation cost ranges from $99 to $199 for the initial visit and $75 to $150 for follow-ups, typically scheduled every three to six months. Laboratory monitoring (total testosterone, free testosterone, hematocrit, PSA, and a comprehensive metabolic panel) is standard at baseline, 3 months, 6 months, and annually thereafter, consistent with the Endocrine Society's monitoring recommendations [3].

For Arizona residents outside the Phoenix and Tucson metro areas, telehealth eliminates a significant access barrier. Counties like Apache, Navajo, and Greenlee have limited endocrinology and urology access, with some patients facing 150-mile drives to reach a prescriber experienced with TRT protocols. Telehealth closes that gap entirely.

Prescriptions generated through telehealth visits can be filled at any Arizona retail pharmacy or shipped from a licensed mail-order pharmacy. Compounding pharmacies also accept telehealth prescriptions, provided the prescription is written on a valid controlled substance prescription form and transmitted according to DEA requirements.

Discount Programs and Savings Cards for Arizona Patients

Multiple discount pathways can reduce testosterone enanthate costs below the $70 per month retail average. The most accessible option: free pharmacy discount cards from GoodRx, RxSaver, or SingleCare, which negotiate pre-set rates with participating pharmacies.

GoodRx pricing for generic testosterone enanthate (200 mg/mL, 1 mL vial) at Arizona pharmacies ranges from $25 to $55 depending on the specific pharmacy. Costco and Walmart tend to offer the lowest discount-card prices, while CVS and Walgreens fall on the higher end. These discount cards cannot be combined with insurance but often beat the insured copay for patients on high-deductible plans.

Manufacturer savings programs for brand-name testosterone products do exist, but they apply primarily to newer formulations like Xyosted (testosterone enanthate autoinjector) and Aveed (testosterone undecanoate). Xyosted's manufacturer, Endo Pharmaceuticals, offers a copay card that can reduce the out-of-pocket cost to as little as $0 for commercially insured patients [8]. This card does not apply to generic testosterone enanthate vials.

The 340B Drug Pricing Program offers another avenue for qualifying patients. Federally qualified health centers (FQHCs) in Arizona, including El Rio Health in Tucson, Mountain Park Health Center in Phoenix, and North Country HealthCare in Flagstaff, can dispense medications at 340B pricing, which is substantially below retail. Not all FQHCs stock testosterone enanthate, but those with on-site pharmacies can order it at the discounted rate and pass savings to uninsured or underinsured patients.

A cost-reduction strategy that clinicians sometimes overlook: prescribing the 10 mL multi-dose vial instead of individual 1 mL vials. For a patient on 100 mg weekly (0.5 mL of 200 mg/mL), a single 10 mL vial lasts 20 weeks. At a cash price of $90 to $120 for the 10 mL vial, that works out to $18 to $24 per month. This approach requires proper storage, sterile technique with each draw, and awareness that multi-dose vials should be discarded 28 days after first puncture per USP 797 guidelines [9].

How Arizona Pricing Compares to Other States

Arizona sits near the national median for testosterone enanthate cash pricing. The $70 per month average falls below high-cost states like California ($85 to $110) and New York ($80 to $100) but above lower-cost markets like Texas ($55 to $70) and Florida ($50 to $65).

Several factors drive state-level price variation. Pharmacy density matters. Arizona has roughly 1,800 licensed retail pharmacies serving 7.4 million residents, yielding moderate competitive pressure. States with higher pharmacy-to-population ratios tend to see lower cash prices due to competition effects. Wholesale acquisition cost is uniform nationally, so the price differences reflect pharmacy markup, local operating costs, and competitive dynamics.

The compounded testosterone enanthate market in Arizona is competitively priced compared to other Western states. Arizona's 503A pharmacy sector benefits from lower commercial rents and operating costs than coastal markets, and the state's relatively permissive compounding regulations keep barriers to entry manageable.

A 2023 study in the Journal of Clinical Endocrinology & Metabolism analyzed testosterone prescribing patterns across 12 states and found that cash-pay prices for injectable testosterone esters varied by up to 300% across pharmacies within the same metropolitan area [10]. Phoenix specifically showed a $25 to $95 range for the same generic testosterone enanthate product, reinforcing the value of price shopping.

Monitoring Costs Beyond the Prescription

The medication itself represents only part of total TRT cost. Arizona patients should budget for diagnostic labs, follow-up visits, and ancillary supplies when calculating the true monthly expense of testosterone replacement.

Initial diagnostic workup runs $150 to $300 for uninsured patients. This includes two morning total testosterone draws (ideally before 10 AM), sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, prolactin, a complete blood count, comprehensive metabolic panel, lipid panel, and PSA for men over 40. Most commercial insurance covers these labs at 100% when coded as diagnostic.

Ongoing monitoring follows the Endocrine Society's 2018 guideline recommendations: measure testosterone and hematocrit at 3 months, 6 months, and then annually [3]. Hematocrit monitoring is particularly important. The guideline states: "Clinicians should measure hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit rises above 54%, stop testosterone therapy until hematocrit decreases to a safe level" [3]. Lab costs for these follow-up panels range from $50 to $150 per visit out of pocket, or $0 to $30 with insurance.

Injection supplies add a small recurring cost. A box of 100 23-gauge 1-inch needles costs $10 to $15, and a corresponding box of 18-gauge drawing needles runs the same. Alcohol swabs, a sharps container, and bandages bring the supply cost to roughly $5 to $8 per month.

Adding it all up for an uninsured Arizona patient paying cash: $70 per month for medication, $5 per month for supplies, and roughly $15 per month amortized lab and visit costs yields a total of approximately $90 per month, or about $1,080 per year. For insured patients with generic copays and covered labs, the total can drop to $20 to $50 per month.

Clinical Evidence Supporting Testosterone Enanthate Therapy

Arizona prescribers base their treatment decisions on a substantial evidence base. The T-Trials (Testosterone Trials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older across 12 U.S. sites with serum testosterone below 275 ng/dL and symptoms in at least one of three domains: sexual function, physical function, or vitality [5]. After 12 months of testosterone gel therapy (the trials used transdermal, though the pharmacokinetic principles apply to enanthate), treated men showed significant improvements in all three symptom domains versus placebo.

Specifically, the Sexual Function Trial demonstrated a mean increase of 0.58 on the Psychosexual Daily Questionnaire (PDQ) activity score versus placebo (P<0.001), a clinically meaningful difference [5]. The Physical Function Trial showed a mean increase in 6-minute walking distance of 6.3 meters versus placebo, a modest but statistically significant gain.

For cardiovascular safety, the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) provided reassuring data. Published in the New England Journal of Medicine in 2023, TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease [11]. The primary composite endpoint of major adverse cardiovascular events was non-inferior in the testosterone group versus placebo (hazard ratio 0.96 to 95% CI 0.78 to 1.17), settling years of concern about testosterone and cardiac risk.

These findings support the ongoing use of testosterone enanthate in appropriately selected patients. Arizona practitioners who follow evidence-based prescribing guidelines can offer TRT with confidence that the benefit-risk profile has been characterized in large, well-designed trials.